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Friedreich’s ataxia (FRDA), the most common inherited ataxia, is characterized by focal neurodegeneration,
diabetes mellitus and life-threatening cardiomyopathy. Frataxin, which is signiﬁcantly reduced in patients
with this recessive disorder, is a mitochondrial iron-binding protein, but how its deﬁciency leads to neurode-
generation and metabolic derangements is not known. We performed microarray analysis of heart and skel-
etal muscle in a mouse model of frataxin deﬁciency, and found molecular evidence of increased lipogenesis
in skeletal muscle, and alteration of ﬁber-type composition in heart, consistent with insulin resistance and
cardiomyopathy, respectively. Since the peroxisome proliferator-activated receptor gamma (PPARg) pathway
is known to regulate both processes, we hypothesized that dysregulation of this pathway could play a key
role in frataxin deﬁciency. We conﬁrmed this by showing a coordinate dysregulation of the PPARg coactiva-
tor Pgc1a and transcription factor Srebp1 in cellular and animal models of frataxin deﬁciency, and in cells
from FRDA patients, who have marked insulin resistance. Finally, we show that genetic modulation of the
PPARg pathway affects frataxin levels in vitro, supporting PPARg as a novel therapeutic target in FRDA.
INTRODUCTION
Friedreich’s Ataxia (FRDA, OMIM #229300) is an inher-
ited autosomal recessive disorder characterized by progress-
ive neurologic disability, cardiomyopathy and, in some
patients, diabetes mellitus (1). FRDA is caused by partial
deﬁciency of the mitochondrial protein frataxin (2).
Though the function of frataxin is still partly controversial,
there is general agreement that it is involved in cellular iron
homeostasis and that its deﬁciency results in multiple
enzyme deﬁcits, mitochondrial dysfunction, and oxidative
damage. Complete absence of frataxin is incompatible
with life in higher organisms, as demonstrated by the
embryonic lethality observed in systemic and conditional
gene knock-out models (3–6).
Residual frataxin amounts vary between 5 and 35% of
normal levels in FRDA patients, and are little more than
50% in heterozygous carriers, who show no sign of disease
(2). A clear pattern of selective vulnerability to this partial
loss of frataxin can be observed in FRDA. In the nervous
system, neurodegeneration affects the large primary sensory
neurons in the dorsal root ganglia and their axons in peripheral
nerves and in the dorsal columns of the spinal cord, the spino-
cerebellar pathways, the dentate nucleus in the cerebellum, the
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the auditory and visual pathways. Cardiac involvement is
present in most patients at the preclinical level, and 45–63%
of FRDA patients have hypertrophic cardiomyopathy, which
can cause premature death (7,8). Overt diabetes is present in
14–19% of FRDA patients, and glucose intolerance is seen
in 24–40% (9–11). Skeletal muscle is only sub-clinically
involved in FRDA, as a reduced ATP production can be
detected with MR spectroscopy (12), but the causal metabolic
pathways have not been identiﬁed.
Reducing frataxin expression in mice to levels similar to
those observed in FRDA (KIKO mice) induced a biochemical
CNS phenotype (13) but not clinical abnormalities (14). To
study the selective vulnerability to frataxin deﬁciency in a
model where no confounding non-speciﬁc or secondary degen-
erative changes are expected to occur, we have utilized
frataxin-deﬁcient mice to investigate gene expression proﬁles
in the heart, a major target of FRDA pathology, and in skeletal
muscle, only sub-clinically affected in the human disease. This
unbiased genome-wide analysis, which we further extended to
liver and cellular models, conﬁrmed the hypothesis that
frataxin deﬁciency causes tissue-speciﬁc changes in several
metabolic pathways. Involvement of the peroxisome-
proliferator activator receptor gamma (PPARg)/PPARg coac-
tivator 1 alpha (Pgc1a) pathway in several cell types may
serve as key regulator of FRDA pathogenesis, including
enhanced risk of diabetes and cardiomyopathy.
RESULTS
Functional genomic analysis of frataxin deﬁcient mice
We analyzed tissue from heart and skeletal muscle from four
KIKO mice compared with control littermates. We used two
array platforms (Agilent G4121A and Illumina Mouse
RefSeq Expression arrays, see Materials and Methods), in
order to increase our detection power. Unsupervised array
clustering clearly separates the two tissues (Fig. 1A), conﬁrm-
ing distinct expression proﬁles. Because cardiac involvement
is most clinically evident, we expected more changes in the
cardiac tissue than skeletal muscle. However, in KIKO mice
versus WT littermates, we found more differentially expressed
(DE) genes in skeletal muscle (n ¼ 321) than in heart (n ¼
174) (Fig. 1B and C), suggesting a level of complexity in
the tissue-speciﬁc response to frataxin deﬁciency that we
had not anticipated. We observed a preponderance of downre-
gulated genes in both tissues. This conﬁrms previous reports in
this (13) and other (15) FRDA models, and suggests that fra-
taxin deﬁciency induces a prevalent downregulation of gene
expression. Furthermore, we observed distinct expression pat-
terns in each muscle type, consistent with distinct downstream
effects of frataxin deﬁciency in these distinct tissues.
Three-hundred and twenty-one probes (corresponding to
308 unique gene names) were DE between KIKO and WT
skeletal muscle. The most DE genes are reported in Sup-
plementary Material, Table S1, and the complete gene list is
reported in Supplementary Material, Table S2. The top Gene
Ontology (GO) categories (Supplementary Material,
Table S1; Fig. 1D) include lipid metabolism (overall upregu-
lated), transcriptional regulation and signal transduction.
Ingenuity Pathway analysis (Supplementary Material,
Fig. S1) showed that a number of targets of the transcriptional
regulator Srebp1 (including Acas2, Scd2 and Aacs) were also
upregulated in skeletal muscle. We also observed increased
levels of Socs3, which has been linked to insulin resistance
(16) and diabetes (17). Interestingly, we found a signiﬁcant
upregulation of the cytosolic malic enzyme 1 (Mod1), con-
ﬁrming a previous report of increased activity in FRDA
muscle biopsies (18). Some contractile proteins were also dys-
regulated (mostly downregulated) in skeletal muscle, includ-
ing Tnn1, Myl3, Tnnc1. We observed an over-representation
of downregulated contractile proteins expressed in slow-twitch
ﬁbers, which would lead to a prevalence of fast, more anaero-
bic, less-oxidative ﬁber type, in contrast to the signature
observed in cardiac muscle (see in what follows).
One-hundred and seventy-four probes (corresponding to
169 unique gene names) showed differential expression in
heart (Supplementary Material, Tables S3 and S4). The top
GO categories (Supplementary Material, Table S3; Fig. 1E)
include ‘regulation of muscle contraction’ (overall downregu-
lated), ‘oxidoreductase activity’ and ‘regulation of cell cycle’.
Ingenuity Pathway analysis (Supplementary Material, Fig. S2)
showed an overrepresentation of mitogen-activated kinase
(Mapk) targets, conﬁrming the involvement of this pathway
as an early biochemical change in response to frataxin
deﬁciency (13). Most strikingly, in heart a number of core pro-
teins of the muscle-ﬁber contractile apparatus showed signiﬁ-
cant downregulation, including Myh4, Tnnc2 and Tnni2
(Supplementary Material, Table S3). Downregulated genes
were mostly associated with aerobic, fast-twitch myoﬁbrils
(e.g. Atp2a1, Tnnc2, Tnni2, Tnnt3)—an opposite trend com-
pared with skeletal muscle. Atp2a1 (also known as sarcoplas-
mic/endoplasmic reticulum calcium ATPase 1, Serca1)i s
involved in calcium sequestration and muscular excitation/
contraction. Downregulation of SERCAs has been associated
with cardiomyopathy in a number of studies (19), and its upre-
gulation is beneﬁcial for cardiac function in animal models
(20). Only 6% of DE genes in heart were also dysregulated
in skeletal muscle, indicating a differential effect of frataxin
deﬁciency on these two metabolically distinct muscle tissues.
We selected 14 genes to represent a cross-section of DE
genes expressed at different levels and in different tissues,
for validation by qPCR. We conﬁrmed 71% of the targets
(Fig. 1F)—a high conﬁrmation rate, considered the magnitude
of the observed changes and the sensitivity of qPCR.
Taken together, these data suggest an upregulation of lipi-
dogenic enzymes in skeletal muscle, and a shift in ﬁber-type
composition in both heart and skeletal muscle, in opposing
directions. In heart, these expression changes, together with
changes in calcium-related genes (21), are compatible with
early signs of cardiomyopathy, whereas in skeletal muscle
(a major insulin target) these data suggest a derangement of
fuel metabolism related to early changes occurring in insulin
resistance and type 2 diabetes (T2D). Pgc1a and the sterol-
responsive element binding protein 1 (Srebp1) are master reg-
ulators of lipid biosynthesis and breakdown (22,23). Pgc1a is
also known to control the muscle ﬁber-type ratio (24), and
both factors are involved in insulin resistance and diabetes
(25–27). Since the dysregulation of these two master tran-
scriptional regulators provides a parsimonious explanation
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observed, we hypothesized that they are directly affected by
frataxin deﬁciency. Further supporting this hypothesis, we
found that other genes whose expression is affected by
Pgc1a [e.g. Mmp9 (28), Fabp3 (29), Socs3 (30)] are also
dysregulated.
We generated cellular models of frataxin deﬁciency using
short hairpin RNA interference (shRNAi) and followed the
effects of transient frataxin downregulation on a set of target
genes identiﬁed in the microarray study. In such models,
expression changes occurring over a short time period (12–
72 h) can be more conﬁdently attributed to a direct, primary
effect of frataxin deﬁciency, rather than a secondary degenera-
tive process due to long-term cellular changes.
Transfection of C2C12 myoblasts with an anti-frataxin
shRNA (shRNAi
Fxn) induced an average 50% downregulation
of the Fxn transcript and protein that started at 12 h, peaked at
24–32 and lasted up to 72 h (Fig. 2A and B). In these cells, we
observed dysregulation of a set of genes already known to be
downstream of frataxin deﬁciency, such as Isu (31) and Mthf
(15), thus validating them as a cellular model of frataxin
deﬁciency. Consistent with our interpretation of the microar-
ray ﬁndings in KIKO skeletal muscle, we found a coordinate
downregulation of Pgc1a and upregulation of Srebp1
Figure 1. Microarray analysis of heart and skeletal muscle in KIKO mice. (A) Array clustering based on mean average deviation shows sample clustering by
tissue. Within tissues, samples tend to cluster by genotype. Color coding bars: Top (genotype): red, WT samples; black, KIKO samples. Left side (tissue): red,
skeletal muscle samples; black, heart samples. (B) Number of differentially expressed genes at P , 0.005. Three-hundred and twenty-one probes (194 down-
regulated, 127 upregulated) were differentially expressed in skeletal muscle; 174 (106 downregulated, 68 upregulated) in heart of KIKO mice versus WT; (C)
Heatmap depicting fold changes in cardiac and skeletal muscle samples in KIKO mice versus controls. Shades of red represent upregulation, shades of green
downregulation. Genes and samples are clustered by similarity. Most genes have tissue-speciﬁc changes, whereas a subset of genes present changes across
tissues. Color coding bar: yellow, skeletal muscle samples (KIKO versus average of WT); orange: heart samples (KIKO versus average of WT); (D and E)
Gene ontology analysis of differentially expressed genes in heart and skeletal muscle samples from KIKO versus WT mice. Top categories include ‘sterol’
and ‘lipid metabolic process’ in skeletal muscle and ‘regulation of muscle contraction’ in heart. Bars represent the –Log of the over-representation P-value,
as calculated by the DAVID algorithm (http://david.abcc.ncifcrf.gov/). Red and green represent the proportion of up and downregulated genes, respectively.
The number at the end of the bar represents the number of probes differentially expressed in each category; (F) Real-time quantitative PCR (qPCR) conﬁrmation
on 14 among the top differentially expressed genes. Fold changes are expressed in log2. Error bars: standard error. qPCR conﬁrmed tissue speciﬁcity (e.g. Myh4
only downregulated in heart, Scd2, Slc2a5, Acly only upregulated in skeletal muscle).
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genes that were upregulated in KIKO skeletal muscle (Elovl3,
Acas2, Acly) also showed a signiﬁcant upregulation in
shRNAi
Fxn-transfected C2C12 cells, peaking at 48 h after
transfection (24 h after frataxin downregulation, Fig. 2A). In
addition, PPAR-binding protein (Pparbp), which was downre-
gulated in brains of KIKO mice and ﬁbroblasts from FRDA
patients (13), was also downregulated.
To check the speciﬁcity for skeletal muscle-derived cells of
the above changes, as suggested the by microarray data, we
generated shRNA
Fxn-transfected HL-1 cardiomyocytes.
Though these cells showed a 40–50% frataxin mRNA down-
regulation, no signiﬁcant changes in lipogenic genes occurred,
whereas Pparbp and Pgc1a showed a non-signiﬁcant trend
towards upregulation (Fig. 2B), in concordance with the
KIKO heart expression proﬁling ﬁndings.
We next tested the hypothesis that the changes observed in
skeletal muscle represent systemic metabolic changes consist-
ent with fuel shift and potential insulin resistance. Because
liver is a major player in fuel metabolism and insulin response,
we analyzed global patterns of gene expression in the liver of
3 KIKO mice compared to 3 WT mice using microarrays. This
Figure 2. C2C12 (A) and HL-1 (B) cells were transfected with shRNAi for frataxin. Expression levels of frataxin versus cells transfected with control shRNAi
were assessed at 12, 24, 32, 48 and 72 h after transfection (top panel). Expression levels of nine genes were assessed at 24 and 48 h after transfection (bottom
panel). Red bars: upregulated genes; green bars: downregulated genes. Fold changes are expressed in log2. Error bars: standard error. Asterisk: P , 0.05, one-
sample t-test. (C) Representative western blots (top) and blot quantiﬁcation (bottom) for Frataxin and Srebp1 after transfection with control shRNAi (left) and
shRNAi
Fxn (right). (D) shRNAi
Fxn transfection reduces Pgc1a expression as measured by a luciferase assay in 293 cells after 24 h. (E) FRDA patients have a
signiﬁcantly lower insulin sensitivity index: boxplots representing the insulin sensitivity index SI [ 10
25 min
21/(mU/ml)] in healthy controls and FRDA
patients, matched for age and body mass index. n ¼ 14 in each group,   P , 0.005 by Wilcoxon rank sum test. (F) In FRDA patients, SI was signiﬁcantly inver-
sely correlated with the number of GAA repeats on the smaller FRDA allele (r ¼ 20.55, P , 0.05). (G) Physical impairment scores are not signiﬁcantly differ-
ent between insulin-resistant and insulin-sensitive patients; the bar graph depicts the SI (left) and the physical impairment scores [on a scale from 0 (normal) to 42
(most severe impairment), right] of the 50% (n ¼ 7) most insulin sensitive (light gray bars) and of the 50% (n ¼ 7) most insulin resistant patients (dark gray
bars); P ¼ 0.5 for comparison between the two groups.
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(Supplementary Material, Fig. S3 and Table S5). Strikingly,
by GO analysis, lipid metabolism was among the top cat-
egories showing a signiﬁcant enrichment in liver (Supplemen-
tary Material, Fig. S3B). Many dysregulated genes were
shared with skeletal muscle (e.g. Acac, Acas2). In addition,
other lipid-related genes showed liver-speciﬁc changes (Sup-
plementary Material, Table S5), consistent with a systemic
metabolic rearrangement towards increased lipogenesis in fra-
taxin deﬁciency. These observations further suggest that
Pgc1a and Srebp1 are likely to play a central role in this tran-
scriptional response. To summarize this concept, a potential
model that is parsimonious with these data is depicted in Sup-
plementary Material, Figure S4.
FRDA patients are insulin resistant
The ﬁnding that gene expression proﬁles in KIKO mice
skeletal muscle and liver were suggestive of decreased
insulin sensitivity prompted us to test insulin sensitivity in
14 non-diabetic FRDA patients by intravenous glucose-
tolerance testing and minimal model analysis of glucose
kinetics. Conﬁrming previous reports (9,32), we found that
non-diabetic FRDA patients were insulin resistant compared
with controls [insulin sensitivity index SI 20+2 in patients
versus 34+3   10
25 min
21/(mU/ml) in healthy controls
matched for age and body mass index, n ¼ 14 in each
group, P , 0.005, Fig. 2E and G]. Furthermore, insulin sensi-
tivity was signiﬁcantly inversely correlated with the number of
GAA repeats in the smaller FRDA allele (r ¼ 20.55, P ,
0.05, Fig. 2F) in FRDA patients, indicating that it is directly
linked to the degree of frataxin deﬁciency. To exclude that
the severity of neurological impairment, possibly because of
the resulting reduced motor activity, rather than the degree
of frataxin depletion was the cause of insulin resistance, we
compared the score on a neurological impairment rating
scale ranging from 0 (normal) to 42 (most severe impairment)
between the 50% more insulin sensitive FRDA patients (n ¼
7) and the 50% more insulin resistant patients (n ¼ 7), and
found no signiﬁcant difference (Fig. 2G), suggesting that fra-
taxin deﬁciency directly causes insulin resistance, independent
of physical impairment.
The PPARg pathway is dysregulated in frataxin deﬁcient
mice and FRDA patients
We assessed whether Pgc1a is dysregulated in additional cell
types, including CNS cells, strengthening the causal connec-
tion between frataxin and Pgc1a downregulation. We cultured
neural precursor cells (NPCs) from the subventricular zone
(SVZ) from homozygous Fxn
(GAA)230 (KIKI) mice (33),
KIKO mice and WT littermates and quantiﬁed Fxn and
Pgc1a transcript levels using RT-qPCR. Pgc1a transcript
levels were decreased by 25% in KIKI- and by 70% in
KIKO-derived NPCs (Fig. 3A).
To extend these observations to human patients, we studied
lymphoblastoid cell lines and primary skin ﬁbroblasts from
FRDA patients. In both cell types we observed a 70–80%
downregulation of PGC1A relative to normal controls
(Fig. 3A). Furthermore, when we examined results from
FRDA ﬁbroblasts, a strong correlation emerged between
PGC1A and FXN expression, normalized to controls (r
2 ¼
0.9, P , 0.001, Fig. 3B).
PPARg manipulation affects frataxin levels
Pgc1a plays a key role in mitochondrial biogenesis and func-
tion by promoting the expression of several genes involved in
mitochondrial DNA replication and in oxidative phosphoryl-
ation (34). The importance of frataxin for normal mitochon-
drial function makes it a possible target of PGC1A,
prompting us to test whether PGC1A manipulation can
affect frataxin levels. We downregulated PGC1A in human
ﬁbroblasts using a speciﬁc siRNA and observed a signiﬁcant
decrease in frataxin mRNA and protein levels after a 72-h
transfection with siRNAi
PGC1A in both FRDA patients and
controls (Fig. 3C and D). Thus, a positive feedback loop
between PGC1A and frataxin levels appears to exist. We
hypothesize that, when frataxin is primarily abnormally low,
as in FRDA, the resulting impairment of this feedback loop
is likely to further aggravate frataxin deﬁciency. Conversely,
a pharmacological intervention to activate PGC1A should
help re-establishing the positive feedback and therefore
increase frataxin levels. The recent report that the potent
PPARg agonist Azelaoyl-PAF (35) is able to increase frataxin
levels in FRDA cells (36) supports this model.
DISCUSSION
Neurodegenerative diseases affect speciﬁc subsets of neurons
and in some cases non-nervous system structures as well,
but the reasons underlying such selective cellular vulnerability
are largely unknown. Reduced frataxin levels in FRDA are
likely to have some downstream consequences that are the
same in all cell types, along with consequences and adaptive
responses that are cell and tissue-speciﬁc. We took an
unbiased, genome-wide approach to obtain clues on FRDA
pathogenesis and selective vulnerability. We analyzed how
global gene expression proﬁles are affected in the heart
(affected in FRDA), skeletal muscle and liver (not clinically
affected) from a mouse model expressing frataxin at levels
(about 30–35% of normal) corresponding to mildly affected
FRDA patients, and yet not showing obvious clinical or
pathological abnormalities. We observed the same basic
pattern of dysregulation in skeletal muscle and liver, consist-
ent with their roles in energy metabolism. However heart
muscle, which is signiﬁcantly affected by myopathy in the
human disease, showed changes suggesting a ﬁber-type
switch and dysregulation of contractile proteins, possibly
consistent with cardiomyopathy.
Dysregulation of the PPARg/PGC1A pathway was
observed in tissues from animal and cellular models of frataxin
deﬁciency, as well as in cells from FRDA patients, suggesting
that this is a general downstream effector of frataxin
deﬁciency. Pgc1a is the most studied of the peroxisome prolif-
erator activated receptor co-activators (PGCs), a family of
transcriptional co-activators that regulate mitochondrial bio-
genesis, energy substrate and utilization, and oxidative meta-
bolism (23). In KIKO skeletal muscle and liver, our results
2456 Human Molecular Genetics, 2009, Vol. 18, No. 13indicate that Pgc1a activity is downregulated, as shown by the
increased expression in both tissues of a set of genes involved
in lipogenesis that are normally repressed by Pgc1a, including
Acas2, Scd2, Acly, Aacs, Elovl3. These changes are also sup-
ported by the simultaneous upregulation of the transcription
factor Srebp1. In skeletal muscle, changes in expression of
contractile proteins that would result in increased glycolytic
fast-twitch ﬁbers and decreased slow, oxidative ﬁbers type I
and IIa, provide further evidence of downregulated Pgc1a
activity (37). Pgc1a downregulation, and the related Srebp1
upregulation, are known to occur in insulin resistance and dia-
betes (38,39), along with reduced mitochondrial oxidative
phosphorylation and lower oxidative-to-glycolytic muscle
ﬁber ratio (40,41). The increased risk of diabetes in FRDA
patients is therefore likely to be a consequence of the downre-
gulation of Pgc1a in key tissues for insulin response and fuel
metabolism control. FRDA patients are insulin resistant before
being diabetic (9), and higher incidence of glucose intolerance
and insulin resistance has been reported in family members of
FRDA patients (42,43). However, other reports suggest a
primary beta-cell involvement in FRDA (44), and a patho-
genic mechanism primarily involving beta-cell failure has
been proposed based on studies in other mitochondrial dis-
orders (45,46) and on the pancreatic conditional frataxin
knock-out (6). Here, we conﬁrm that insulin resistance is
present in all tested non-diabetic FRDA patients, strongly sup-
porting the hypothesis suggested by our gene expression data
that insulin target tissues are relevant in the pathogenesis of
diabetes in FRDA. Furthermore, we show here for the ﬁrst
time that the degree of insulin resistance of FRDA patients
correlates with GAA repeat size (hence to lower residual fra-
taxin levels) and is independent of neurological impairment, in
agreement with the hypothesis that it is a direct consequence
of frataxin deﬁciency.
Though the direct mechanistic link between frataxin and
PGC1A remains to be completely deﬁned, it is very likely
related to mitochondrial dysfunction caused by frataxin
deﬁciency. Mitochondrial dysfunction also occurs in T2D
(47), as shown by 30% reduction of ATP production in skel-
etal muscle, associated with increased intramyocellular lipid
(IML) content and decreased aerobic/anaerobic muscle ﬁber
ratio (40,48). IML content, a consequence of increased lipid
synthesis, is strongly correlated with glucose intolerance and
insulin resistance in diabetic patients and can trigger insulin
resistance (26). No data are available on IMLs in FRDA
muscle, but the ﬁnding of increased cytosolic malic enzyme
activity (18), in perfect concordance with gene expression
data from KIKO mice, at least suggests increased lipogenesis
Figure 3. Genetic and pharmacologic modulation of the PPARg pathway affects frataxin levels in vitro.( A and B) Pgc1a levels are correlated with frataxin
levels in neural precursor cells from mouse models and in cells from patients with FRDA. (A) qPCR quantiﬁcation of Fxn (white bars) and Pgc1a (blue
bars) in neural precursor cells from the subventricular zone (SVZ-NPC) in wild-type (WT, n ¼ 3), KIKI (n ¼ 3) and KIKO (n ¼ 3) mice, and in lymphoblasts
and ﬁbroblasts from FRDA patients (n ¼ 4) and normal controls (n ¼ 3). KIKI mice express 75% of normal frataxin levels, and KIKO 30%. Pgc1a mRNA
expression levels are reduced in all these cell lines, in a degree which is proportional to Fxn downregulation. Bars represent the average of six replicates, error
bars represent the standard error. P , 0.05 for all the comparisons; (B) Relative Pgc1a levels are strongly correlated with relative Fxn mRNA levels (r
2 ¼ 0.9,
P , 0.001); qPCR quantiﬁcation in ﬁbroblasts from controls (open circles, n ¼ 3) and FRDA patients (ﬁlled circles, n ¼ 4). (C and D) PGC1A downregulation
via siRNAi reduces frataxin protein levels in control ﬁbroblasts, and further in FRDA ﬁbroblasts. Western blotting analysis (C) and quantiﬁcation (D) of PGC-1A
(top) and FXN (bottom) protein 72 h after transfection with siRNAi
Pgc1a. Control and FRDA are ﬁbroblasts from healthy controls and patients, respectively. All
experiments were performed on n ¼ 4 FRDA cell lines and n ¼ 3 control cell lines. Bars represent the average of six replicates, error bars represent the standard
error. P , 0.05 for all comparisons.
Human Molecular Genetics, 2009, Vol. 18, No. 13 2457and a metabolic shift similar to T2D. We propose therefore
that in FRDA, like in T2D, a state of insulin resistance and
associated metabolic changes long precedes the onset of clini-
cally overt diabetes, which is eventually due to pancreatic
beta-cell failure. Beta-cell failure may in turn be accelerated
by intrinsic mitochondrial dysfunction due to the gene defect
(Fig. 4).
In contrast with skeletal muscle, we observed a downregu-
lation of fast ﬁbers in cardiac muscle, which also suggests an
increased Pgc1a effect. We also observed a trend towards
Pgc1a upregulation in HL-1 cardiomyocytes treated with
shRNAi
Fxn. Though apparently contradictory, these data actu-
ally conﬁrm Pgc1a as a primary target of frataxin deﬁciency
while underlining tissue-speciﬁc differences in this response.
Our ﬁndings are indeed consistent with the observation that
Pgc1a mRNA levels are elevated in the myocardium in a
mouse model of metabolic syndrome (49) and with data
suggesting a role for increased Pgc1a levels in diabetic cardio-
myopathy (50). Furthermore, chronic overexpression of Pgc1a
in hearts of transgenic mice induces cardiomyopathy (51,52),
while only mild cardiac abnormalities are observed in the
hearts of Pgc1a knock-out mice (53,54). The idea that Pgc1a
can have opposite changes in different tissues is supported
by the fact that its overexpression induces uncoupled respir-
ation in adipose tissue and coupling in cardiac myocytes
(51). Pgc1a binding to tissue-speciﬁc transcription factors,
enabling the activation of diverse metabolic programs in
different tissues (23,55), offers an explanation for these differ-
ences and the distinct metabolic effects observed in skeletal
and cardiac muscle in this model of frataxin deﬁciency (Sup-
plementary Material, Fig. S4).
This model was supported by recent reports that (i) PGC1A
overexpression in skeletal muscle cells (56) and (ii) treatment
of FRDA cells with the PPARg agonist Azelaoyl-PAF (36) are
able to increase frataxin levels. PPARg agonists such as rosi-
glitazone and pioglitazone are in clinical use as oral antidia-
betics. The latter molecule may be of particular interest
because of its capacity to cross the blood–brain barrier.
Clearly, the opposite dysregulation of Pgc1a in the heart
imposes caution for any attempt to clinically test such a
drug in FRDA. Maybe not surprisingly, cardiac toxicity is a
known side effect of this class of drugs.
In conclusion, we have identiﬁed distinct pattern of gene
expression changes in metabolically distinct tissues in
Figure 4. Diabetes in FRDA and type-2 diabetes may have a ﬁnal common pathway. In normal conditions (left panel), lipid breakdown and biosynthesis are
tightly controlled by the two master regulators Pgc-1a and Srebp-1. In type-2 diabetes (center), increased dietary lipids provided to the skeletal muscle can over-
load TCA and divert long-chain-CoA species into lipid precursors than can be converted in lipids, leading to an increased lipid intramyocellular content, which in
turn leads to reduced glucose transport, reduced glycogen synthesis and ultimately to insulin resistance. In FRDA (right), deﬁcits of TCA enzymes occur, as well
as decreased activity of complexes I–II–III of the respiratory chain. An ineffective TCA and mitochondrial OXPHOS would lead to TCA overﬂow, favoringa
metabolic shift toward the redirection of citrate from the TCA cycle and electron transport chain to processing into fatty acids. In mitochondrial diseases and in
FRDA in particular, the oxidative stress can contribute to the diabetes pathogenesis at both (i) skeletal muscle and liver (insulin targets) and (ii) the beta-cell
level, leading to overt diabetes mellitus. TCA, tricarboxylic acid cycle; IMLs, intra-myocellular lipids.
2458 Human Molecular Genetics, 2009, Vol. 18, No. 13a model of frataxin deﬁciency. These data suggest Pgc1a as a
key regulator of gene expression that is directly affected by
frataxin deﬁciency and in turn affects frataxin expression.
Further studies (such as frataxin overexpression) are needed
to characterize the relationship between Fxn and Pgc1a.
Downregulation of Pgc1a is the rule in several frataxin-
deﬁcient cell types, including skeletal muscle, liver, lympho-
blasts, ﬁbroblasts and possibly the pathologically relevant
CNS cells, engaging a feedback loop that leads to even
lower frataxin levels, reduced antioxidant defenses and mito-
chondrial function. Such a mechanism appears to be respon-
sible in particular for the vulnerability to diabetes of FRDA
patients. In these cell types, upregulation of Pgc1a using
PPARg agonists may be an appealing therapeutic approach.
MATERIALS AND METHODS
Animals and tissue samples
Frataxin knockout/knockin (Frda
230GAA/-, KIKO) and knockin/
knockin (Frda
230GAA/230GAA, KIKI) mice were obtained
as described (14). Four 6-month-old male KIKO and three
6-month-old male KIKI mice were compared with age and
gender-matched WT littermates. Total RNA from skeletal
muscle (gastrocnemius), heart and liver was extracted by
acid phenol extraction (Trizol, GIBCO/BRL) as recommended
by the manufacturer.
Microarrays
Sample preparation and array hybridization and scanning were
performed according to established protocols (detailed in Sup-
plementary Material). Quality control, differential expression,
and cross-platform microarray analysis were performed using
Bioconductor packages in the R statistical environment (see
Supplementary Material for a detailed description). The
microarray data have been deposited in the NCBI Gene
Expression Omnibus database (GEO, www.ncbi.nlm.nih.gov/
geo) with the GEO series accession number GSE15849.
Cell culture
C2C12 cells were obtained from ATCC (Manassas, VA) and
HL-1 cells were a kind gift from the Claycomb Lab (School
of Medicine, LSU, New Orleans, LA). Fibroblasts primary
cell cultures were obtained from skin biopsies of FRDA
patients and healthy controls after receiving written informed
consent. All the patients were homozygous for the GAA repeat
expansion (500–1700 repeats), and were being treated with
Idebenone 5 mg/kg. Epstein Barr virus-transformed lympho-
blast cell lines GM15850 were from a FRDA patient (650–
1030 GAA repeats; NIGMS, Human Genetic Cell Repository
at the Coriell Institute, Camden, NJ, USA) and GM15851
from one unaffected control. Mouse neuronal precursor cells
(NPC-SVZ) were obtained from wild-type and from KIKI/
KIKO mice. Brain layer of tissue surrounding the ventricles
was cultured in the media containing 20 ng/ml recombinant
human EGF and 10 ng/ml recombinant human bFGF
(Peprotech, NJ, USA). Derived neurospheres were plated in
a fresh growth medium and were assessed for their character-
istics of self-renewal and multipotentiality. Cells were trans-
fected using standard procedures, detailed in Supplementary
Material.
qPCR experiments
Real-time quantitative PCR experiments were performed as
described previously (13) and in Supplementary Material,
Methods.
Western blot and luciferase assays
Western blot and luciferase assays were performed using stan-
dard procedures, detailed in Supplementary Material,
Methods.
Assessment of physical impairment in FRDA patients
Speech, upright stability, upper limb coordination, and lower
limb coordination scores from the FARS (57) scale were used.
Assessment of insulin sensitivity in FRDA patients
and healthy controls
FRDA patients and healthy volunteers provided written
informed consent. After an overnight fast, subjects underwent
an intravenous glucose-tolerance test to measure insulin sensi-
tivity. Glucose (0.3 g/kg) was infused intravenously, followed
by an insulin infusion (0.025 U/kg) 20 min later, and blood
was sampled at times 215, 25 and 21 min before intrave-
nous glucose administration, and at 2, 3, 4, 5, 6, 8, 10, 14,
16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90,
100, 120, 140, 160 and 180 min (58). Plasma glucose was
measured using the glucose oxidase method (DiaSys,
Holzheim, Germany). Plasma insulin concentrations were
measured by ELISA (INSI-CTK immunoradiometric analysis;
DiaSorin, Saluggia, Italy). Insulin sensitivity was quantiﬁed as
the insulin sensitivity index (SI) based on the glucose and
insulin data using the minimal model of glucose kinetics (59).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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